[Skip to Content]
[Skip to Content Landing]
Invited Commentary
April 2018

Technological Advances, Biologic Rationales, and the Associated Success of Chemotherapy With Hyperthermia in Improved Outcomes in Patients With Sarcoma

Author Affiliations
  • 1Radiation Oncology, Biomedical Engineering, Basic Science, Duke Cancer Institute, Duke University School of Medicine, Pratt School of Engineering, Durham, North Carolina
  • 2Radiation Oncology, Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina
JAMA Oncol. 2018;4(4):493-494. doi:10.1001/jamaoncol.2017.4941

Soft tissue sarcomas are a heterogeneous group of mesenchymal tumors that account for approximately 12 000 new cancer cases and almost 5000 deaths each year in the United States. For large (>5 cm), high-grade sarcomas of the extremity, surgical resection and radiation therapy can achieve local control in approximately 90% of patients.1,2 However, these patients are at risk for developing metastases to the lung. Therefore, in some sarcoma centers, patients with high-risk, localized sarcoma also receive chemotherapy. Even with systemic therapy, many patients die. Therefore, the European Organization for Research and Treatment of Cancer (EORTC) initiated a multinational, multi-institutional phase 3 randomized clinical trial (EORTC 62961-ESHO 95) to evaluate whether adding regional hyperthermia to chemotherapy improves outcomes for patients with localized high-risk soft tissue sarcoma.